A new, once-daily, optimized, fixed combination of clindamycin phosphate 1.2% and low-concentration benzoyl peroxide 2.5% gel for the treatment of moderate-to-severe acne

Journal of Clinical and Aesthetic Dermatology

Volumn 2, Issue 5, 2009, Pages 44-48

  Gold, Michael H ^a  

^a GOLD SKIN CARE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACANYA; BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE; UNCLASSIFIED DRUG;

ACNE; ARTICLE; CLINICAL FEATURE; DISEASE SEVERITY; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PATIENT SATISFACTION; SCORING SYSTEM; TREATMENT DURATION; TREATMENT INDICATION;

EID: 77954295734     PISSN: 19412789     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. White GM. Recent findings in the epidemiologic evidence, classification and subtypes of acne vulgaris. J Am Acad Dermatol. 1998;39(Suppl):S34-37.
2. Gollnick H, Cunliffe W, Berson D, et al. Management of acne: a report from the alliance to improve outcomes in acne. J Am Acad Dermatol. 2003;49(Suppl):S1-38.
3. Webster GF, Jeyden JJ, McGinley KJ, McArthur WP. Suppression of polymorphonuclear leucocyte chemotactic factor production in Propionibacterium acnes by subminimal inhibitory concentrations of tetracycline, ampicillin, minocycline, and erythromycin. Antimicrob Agents Chemother. 1982;21:770-772.
4. Gupta AK, Lynde CW, Kunynetz RA, et al. A randomized, double-blind, multicenter, parallel group study to compare relative efficacies of the topical gels 3% erythromycin/5% benzoyl peroxide and 0.025% tretinoin/erythromycin 4% in the treatment of moderate acne vulgaris of the face. J Cutan Med Surg. 2003;7:31-37.
5. Waller JM, Dreher F, Behnam S, et al. Keratolytic properties of benzoyl peroxide and retinoic acid resemble salicylic acid in man. Skin Pharmacol Physiol. 2006;19:283-289.
6. Cunliffe WJ, Holland KT, Bojar R, Levy SF. A randomized, double-blind comparison of a clindamycin phosphate/ benzoyl peroxide gel formulation and a matching clindamycin gel with respect to microbiologic activity and clinical efficacy in the topical treatment of acne vulgaris. Clin Ther. 2002;24:1117-1133.
7. Leyden J, Kaidby SF, Levy K. The combination formulation of clindamycin 1% plus benzoyl peroxide 5% versus three different formulations of topical clindamycin alone in the reduction of Propionibacterium acnes. Am J Clin Dermatol. 2001;2:263-266.
8. Lookingbill DP, Chalker DK, Lindholm JS, et al. Treatment of acne with a combination clindamycin/benzoyl peroxide gel compared with clindamycin gel, benzoyl peroxide and vehicle gel: combined results of two double-blind investigations. J Am Acad Dermatol. 1997;37:590-595.
9. Haustein UF, Tegetmeyer L, Ziegler V. Allergic and irritant potential of benzoyl peroxide. Contact Dermatitis. 1985;13:252-257.
10. Bárány E, Lindberg M, Loden, M. Biophysical characterization of skin damage and recovery after exposure to different surfactants. Contact Dermatitis. 1999;40:98-103.
11. Effendy I, Maibach HI. Surfactants and experimental irritant contact dermatitis. Contact Dermatitis. 1995;33(4):217-225.
12. Cserháti T. Alkyl ethoxylated and alkylphenol ethoxylates nonionic surfactants: interaction with bioactive compounds and biological effects. Environ Health Perspect. 1995;103(4):358-364.
13. Soni MG, Taylor NA, Greenberg NA, et al. Evaluation of the health aspects of methyl paraben: a review of the published literature. Food Chem Toxicol. 2002;40(10): 1335-1337.
14. Bucks D, Yu K, Angel A, Del Rosso J. Can delivery be enhanced and skin irritation minimized using a lower concentration of benzoyl peroxide in a fixed combination product? Poster presented at: 67th Annual Meeting of the American Academy of Dermatology; March 6-10, 2009; San Francisco, California.
15. Tucker R, Walton S. The role of benzoyl peroxide in the management of acne vulgaris. Pharm J. 2007;279:48-53.
16. Mills OH Jr, Kligman AM, Pochi P, Comite H. Comparing 2.5%, 5%, and 10% benzoyl peroxide on inflammatory acne vulgaris. Int J Dermatol. 1986;25:664-667.
17. Kligman AM, Leyden JJ, Stewart R. New uses for benzoyl peroxide: a broad-spectrum antimicrobial agent. Int J Dermatol. 1977;16:413-417.
18. Krakowski AC, Eichenfield LF. Pediatric acne: clinical presentations, evaluation, and management. J Drugs Dermatol. 2007;6(6):589-593.
19. Krakowski AC, Stendardo S, Eichenfield LF. Practical considerations in acne treatment and the clinical impact of topical combination therapy. Pediatr Dermatol. 2008;25(Suppl 1):1-14.
20. Niemeier V, Kupfer J, Gieler U. Acne vulgaris-psychosomatic aspects. J Dtsch Dermatol Ges. 2006;4(12): 1027-1036.
21. Hawkins T. Impact of onceand twice-daily dosing regimens on adherence and overall safety. AIDS Read. 2004;14(6):320-322.
22. Richter A, Anton SE, Koch P, Dennett SL. The impact of reducing dose frequency on health outcomes. Clin Ther. 2003;25(8):2307-2335.
23. Serup J, Lindblad AK, Maroti M, et al. To follow or not to follow dermatological treatment: a review of the literature. Acta Derm Venereol. 2006;86:193-197.
24. Thiboutot D, Zaenglein A, Weiss J, et al. An aqueous gel fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 2.5% for the once-daily treatment of moderate-to-severe acne vulgaris: assessment of efficacy and safety in 2,813 patients. J Am Acad Dermatol. 2008;59:792-800.
25. Data on file; Arcutis Pharmaceuticals, Redwood City, California.
26. McEvoy B, Nydegger R, Williams G. Factors related to patient compliance in the treatment of acne vulgaris. Int J Dermatol. 2003;42:274-280.
27. Tan JK, Vasey K, Fung KY. Beliefs and perceptions of patients with acne. J Am Acad Dermatol. 2001;44: 439-445.
28. Weiss J, Fowler J, Yu K, Swinyer. Patient-reported outcomes using a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel for the treatment of moderate-to-severe acne in 2,813 patients. Poster presented at: 67th Annual Meeting of the American Academy of Dermatology; March 6-10, 2009; San Francisco, California.
29. Bucks D, Sarpotdar P, Yu K, Angel A, Del Rosso J. The development and optimization of a fixed combination of clindamycin and benzoyl peroxide aqueous gel with minimal irritation and enhanced bioavailability. J Drugs Dermatol. Accepted for publication.